This clinical trial is focused on studying treatments for two blood-related diseases: Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Neoplasia. The study will explore the effects of a treatment combination that includes a medication called Magrolimab, which is given as a solution through a vein, along with intensive chemotherapy. The chemotherapy may include drugs like Cytarabine and Daunorubicin, which are also administered through a vein. The purpose of the study is to evaluate the effectiveness of this treatment combination in patients who are newly diagnosed with AML and are considered to have an intermediate or poor risk according to specific medical guidelines. These patients are also intended to undergo a procedure called allogeneic stem cell transplantation, which involves replacing diseased bone marrow with healthy cells from a donor.
The study will follow a specific course where participants will receive the treatment over a period of time, with the aim of achieving the best possible response during the initial phase of chemotherapy. This phase is known as induction chemotherapy, which is the first step in treating these diseases. The study will monitor the participants’ health and response to the treatment, including any side effects they may experience. The goal is to determine how well the treatment works in achieving complete remission, which means the absence of disease symptoms, and to assess the overall survival and quality of life of the participants.
Participants will be closely observed throughout the study to gather information on their progress and any changes in their condition. The study will also collect data on the rate of successful stem cell transplants and the impact of the treatment on the participants’ quality of life. This information will help researchers understand the potential benefits and risks of using Magrolimab in combination with intensive chemotherapy for treating Acute Myeloid Leukemia and High-risk Myelodysplastic Neoplasia.
Germany 
